Sagimet Biosciences Inc. (SGMT)
- Previous Close
3.9300 - Open
3.9800 - Bid 3.7800 x 300
- Ask 3.8500 x 300
- Day's Range
3.7800 - 4.1200 - 52 Week Range
1.7300 - 7.3800 - Volume
890,201 - Avg. Volume
585,640 - Market Cap (intraday)
123.308M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-1.4500 - Earnings Date May 15, 2025 - May 29, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
30.38
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs, such as various solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
www.sagimet.comRecent News: SGMT
View MorePerformance Overview: SGMT
Trailing total returns as of 5/2/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SGMT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SGMT
View MoreValuation Measures
Market Cap
126.53M
Enterprise Value
-24.64M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.81
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-26.49%
Return on Equity (ttm)
-36.92%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-45.57M
Diluted EPS (ttm)
-1.4500
Balance Sheet and Cash Flow
Total Cash (mrq)
151.25M
Total Debt/Equity (mrq)
0.05%
Levered Free Cash Flow (ttm)
-29.73M